Cargando…
A novel strategy for the manufacture of idelalisib: controlling the formation of an enantiomer
A novel and scalable synthesis of 5-fluoro-3-phenyl-2-[(1S)-1-(9H-purin-6-ylamino)propyl]-4(3H)-quinazolinone, idelalisib 1, has been developed. This strategy controls the desfluoro impurity of 13 during reduction of nitro intermediate 4, and also arrests the formation of the enantiomer during cycli...
Autores principales: | Mekala, Nagaraju, Buddepu, Srinivasa Rao, Dehury, Sanjay K., Moturu, Krishna Murthy V. R., Indukuri, Sunil Kumar V., Vasireddi, Umamaheswara Rao, Parimi, Atchuta R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Royal Society of Chemistry
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9080089/ https://www.ncbi.nlm.nih.gov/pubmed/35539498 http://dx.doi.org/10.1039/c8ra00407b |
Ejemplares similares
-
Idelalisib for the Treatment of Chronic Lymphocytic Leukemia
por: Khan, Maliha, et al.
Publicado: (2014) -
Idelalisib: a rare cause of enterocolitis
por: Balagoni, Harika, et al.
Publicado: (2016) -
Successful Management of an Occupational High-Voltage Electric Injury Associated With High-Risk Factors and a Clinically Significant Arrhythmia
por: Dharanindra, Moturu, et al.
Publicado: (2023) -
Idelalisib may have the potential to increase radiotherapy side effects
por: Gryc, Thomas, et al.
Publicado: (2017) -
A New Rapid and Sensitive Stability-Indicating UPLC Assay Method for Tolterodine Tartrate: Application in Pharmaceuticals, Human Plasma and Urine Samples
por: Yanamandra, Ramesh, et al.
Publicado: (2012)